Innomicropharmaceuticals MVR-T3011 (intratumor injection) clinical phase II first case of drug delivery completed simultaneously in China and the United States

Innomicropharmaceuticals announced that its leading oncolytic virus product MVR-T3011 intratumoral injection (MVR-T3011 IT) phase II clinical study will be completed on May 28 and June 11, 2021, in China and the United States, respectively.
Medicine
.

MVR-T3011 is a new generation of recombinant herpes oncolytic virus with independent intellectual property rights of Innomicro.
Its virus backbone design is derived from the company's unique insights on oncolytic virus innovation and excellent genetic modification technology.
At the same time, PD- is introduced into the virus backbone.
1 Antibody and IL-12 exogenous gene to further strengthen the anti-tumor immune response of the product
.

MVR-T3011 is the first product pipeline of Innovo to enter the clinical stage
.

The phase I clinical study in China started the first dosing in April 2020, and the first dosing in the United States and Australia in September 2020
.

The preliminary study data of clinical phase I showed ideal safety and effectiveness, and no dose-limiting toxicity was observed in subjects in the clinical phase I carried out in the three places
.

The Phase IIa clinical study in the United States will include two parts: MVR-T3011 as a single agent for melanoma and metastatic solid tumors; and a combination of MVR-T3011 and PD-1 antibody for non-small cell lung cancer
.

The Phase IIa clinical trial in China will start with three single-drug trials for head and neck cancer, sarcoma and breast cancer
.

Through the international multi-center clinical development strategy, Yinuo Micromedicine can efficiently and cost-effectively cover a variety of indications in order to rapidly advance the cross-regional clinical development of MVR-T3011
.

"Relying on the company's OvPENS new drug R&D platform, InnoMicro has become a pioneer in the field," said Dr.
Zhou Guoying, Chairman of InnoMicro.
"InnoMicro will maximize the team's long-term development in oncolytic virus drug development.
Experience and creative insights, design a rich product pipeline, to provide effective, innovative and safe oncolytic virus monotherapy and combination therapy for the anti-tumor market
.

” Following Professor Bernard Roizman's resignation in February 2020 due to high age After Nuowei Pharmaceutical's chairman, Dr.
Zhou Guoying succeeded as the company's chairman and CEO, leading the company's development and strategy in all aspects
.

Note: MVR-T3011 is the official name of the T3011 product pipeline, and T3011 is the product code used to register clinical trials in the United States and China
.

About Yinuowei Medicine Yinuowei Medicine is a biotechnology company dedicated to the development of a new generation of genetically modified herpes oncolytic viruses as cancer treatments
.

Based on its OvPENS (OV+ Potent, Enabling, Novel & Safe) platform, the company has developed and constructed a complete set of scientific logic, R&D technology and production process to support the development and commercialization of oncolytic virus anti-tumor single drugs and combination drugs
.

The OvPENS platform includes five modules: basic research, patented technology, genetic recombination technology, production technology, and commercial analysis, enabling the preclinical and clinical research and development of a new generation of oncolytic viruses with high efficiency, safety and innovation
.